

CLAIMS

1. A corneal nerve axon extension promoter comprising a somatostatin receptor agonist.

5

2. An agent for the recovery of corneal sensitivity, which comprises a somatostatin receptor agonist.

3. A therapeutic agent for dry eye, which comprises a
10 somatostatin receptor agonist.

4. A therapeutic agent for corneal epithelial defect, which comprises a somatostatin receptor agonist.

15 5. A pharmaceutical composition for promoting extension of corneal nerve axon, which comprises a somatostatin receptor agonist.

20 6. A pharmaceutical composition for the recovery of corneal sensitivity, which comprises a somatostatin receptor agonist.

7. A pharmaceutical composition for the treatment of dry eye, which comprises a somatostatin receptor agonist.

25 8. A pharmaceutical composition for the treatment of corneal epithelial defect, which comprises a somatostatin receptor agonist.

9. Use of a somatostatin receptor agonist for the production
30 of a pharmaceutical composition for promoting extension of corneal nerve axon.

10. Use of a somatostatin receptor agonist for the production

of a pharmaceutical composition for the recovery of corneal sensitivity.

11. Use of a somatostatin receptor agonist for the production
5 of a pharmaceutical composition for the treatment of dry eye.

12. Use of a somatostatin receptor agonist for the production
of a pharmaceutical composition for the treatment of corneal
epithelial defect.

10

13. A method of promoting extension of corneal nerve axon,
which comprises administering an effective amount of a
somatostatin receptor agonist to a case in need of the
promotion of extension of the corneal nerve axon.

15

14. A method of recovering corneal sensitivity, which
comprises administering an effective amount of a somatostatin
receptor agonist to a case in need of the recovery of corneal
sensitivity.

20

15. A method of treating dry eye, which comprises
administering an effective amount of a somatostatin receptor
agonist to a case affected with dry eye.

25 16. A method of treating corneal epithelium defect, which
comprises administering an effective amount of a somatostatin
receptor agonist to a case having corneal epithelial defect.